The New England journal of medicine, 2022-01, Vol.386 (4), p.305-315
- Gottlieb, Robert L
- Vaca, Carlos E
- Paredes, Roger
- Mera, Jorge
- Webb, Brandon J
- Perez, Gilberto
- Oguchi, Godson
- Ryan, Pablo
- Nielsen, Bibi U
- Brown, Michael
- Hidalgo, Ausberto
- Sachdeva, Yessica
- Mittal, Shilpi
- Osiyemi, Olayemi
- Skarbinski, Jacek
- Juneja, Kavita
- Hyland, Robert H
- Osinusi, Anu
- Chen, Shuguang
- Camus, Gregory
- Abdelghany, Mazin
- Davies, Santosh
- Behenna-Renton, Nicole
- Duff, Frank
- Marty, Francisco M
- Katz, Morgan J
- Ginde, Adit A
- Brown, Samuel M
- Schiffer, Joshua T
- Hill, Joshua A
2022
Volltextzugriff (PDF)
Details
- Autor(en) / Beteiligte
- Gottlieb, Robert L
- Vaca, Carlos E
- Paredes, Roger
- Mera, Jorge
- Webb, Brandon J
- Perez, Gilberto
- Oguchi, Godson
- Ryan, Pablo
- Nielsen, Bibi U
- Brown, Michael
- Hidalgo, Ausberto
- Sachdeva, Yessica
- Mittal, Shilpi
- Osiyemi, Olayemi
- Skarbinski, Jacek
- Juneja, Kavita
- Hyland, Robert H
- Osinusi, Anu
- Chen, Shuguang
- Camus, Gregory
- Abdelghany, Mazin
- Davies, Santosh
- Behenna-Renton, Nicole
- Duff, Frank
- Marty, Francisco M
- Katz, Morgan J
- Ginde, Adit A
- Brown, Samuel M
- Schiffer, Joshua T
- Hill, Joshua A
- Titel
- Early Remdesivir to Prevent Progression to Severe Covid-19 in Outpatients
- Ist Teil von
- The New England journal of medicine, 2022-01, Vol.386 (4), p.305-315
- Ort / Verlag
- United States: Massachusetts Medical Society
- Erscheinungsjahr
- 2022
- Quelle
- MEDLINE
- Beschreibungen/Notizen
- Among nonhospitalized patients with Covid-19–related symptoms that began less than a week previously, a 3-day course of remdesivir resulted in an 87% lower risk of hospitalization or death than placebo. Adverse effects in the remdesivir group were similar to those in the placebo group.
- Sprache
- Englisch
- Identifikatoren
- ISSN: 0028-4793eISSN: 1533-4406DOI: 10.1056/NEJMoa2116846Titel-ID: cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8757570
- Format
- –
- Schlagworte
- Adenosine Monophosphate - adverse effects, Adenosine Monophosphate - analogs & derivatives, Adenosine Monophosphate - therapeutic use, Adult, Adverse events, Age, Aged, Aged, 80 and over, Alanine - adverse effects, Alanine - analogs & derivatives, Alanine - therapeutic use, Antiviral Agents - adverse effects, Antiviral Agents - therapeutic use, Antiviral drugs, Clinical trials, Comorbidity, Confidence intervals, Coronavirus, Coronaviruses, COVID-19, COVID-19 - complications, COVID-19 - drug therapy, COVID-19 - mortality, Death, Diabetes, Diabetes mellitus, Disease Progression, Double-Blind Method, Double-blind studies, Enrollments, Female, Hospitalization, Hospitalization - statistics & numerical data, Humans, Infectious Disease, Influenza, Intravenous administration, Male, Middle Aged, Monoclonal antibodies, Mortality, Nursing, Obesity, Original, Outpatients, Patients, Placebos, Questionnaires, Risk factors, RNA polymerase, SARS-CoV-2 - drug effects, Severe acute respiratory syndrome coronavirus 2, Statistical analysis, Time-to-Treatment, Viral infections, Viral Load